CTOs on the Move

Aduro Biotech

www.aduro.com

 
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.aduro.com
  • 626 Bancroft Way #3C
    Berkeley, CA USA 94710
  • Phone: 510.848.4400

Executives

Name Title Contact Details

Similar Companies

Datavant

Datavant connects healthcare data to eliminate the silos of healthcare information that hold back innovative medical research and improved patient care. We help data owners manage the privacy, security, compliance, and trust required to enable safe data sharing. Datavant`s vision is backed by Roivant Sciences, Softbank, and Founders Fund, and combines technical leadership and healthcare expertise. Datavant is located in the heart of San Francisco`s Financial District.

Acclaimed Home Care

Acclaimed Home Care is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Segra

Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.

Joule Unlimited

Joule has pioneered a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Free of feedstock constraints and complex processing, this platform can achieve unrivaled scalability, volumes and costs without the use of any agricultural land, fresh water or crops. Unlike products derived with complexity from petroleum or biomass, Joule Sunflow® products are produced in a direct, continuous process from abundant resources. The novel CO2-to-liquids conversion requires only sunlight, non-potable water and engineered bacteria that function as living catalysts to produce specific products, including ethanol and hydrocarbon fuels that are inherently compatible with existing infrastructure. Joule’s highly efficient process and production system are well suited for deployment around the world, unhindered by land or resource constraints. This uniquely modular system can achieve replicable productivity, whether installed across 100 or 1,000 acres, mitigating scale-up risks and ensuring stability of supply. At full-scale commercialization in ideal locations, the company ultimately targets 25,000 US gallons of Joule Sunflow®-E (solar ethanol) or 15,000 US gallons of Joule Sunflow®-D (solar diesel) per acre annually, for approximately $1.20/US gallon ($50/barrel). Joule has successfully pilot-tested its platform for over two years, initiated demonstration-scale operations, and assembled a specialized team to lay the groundwork for commercial deployment. The company is moving rapidly to commercialize Joule Sunflow-E, with Joule Sunflow-D and additional hydrocarbon fuels to follow. Joule is privately held and has raised approximately $200 million in funding to date. The company was founded within Flagship VentureLabs™, and operates out of Bedford, Massachusetts and The Hague, The Netherlands, with production operations in Hobbs, New Mexico.

Intrinsic Medicine

Making Medicine From Milk